CLAIMS

What is claimed is:

1. Use of a pharmaceutical composition comprising:

at least one purified viral L1 protein, wherein the at least one purified viral L1 is a human papilloma virus (HPV) L1 protein and is free of host-cell and/or non-L1 HPV peptide,

a second active pharmaceutical ingredient wherein the second active pharmaceutical ingredient is a local anesthetic, and the local anesthetic is lidocaine; and

a pharmaceutically-acceptable carrier,

in the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered by injection to a subject.

2. The use of claim 1, wherein the medicament comprises a purified viral L1 protein from each of HPV types 6, 11, 16 and 18.

3. The use of claim 1, wherein the medicament comprises a purified viral L1 protein from each of HPV types 16, 18, 31, 33, 45, 52 and 58.

4. The use of any one of claims 1 to 3, wherein the at least one purified viral L1 protein is present in a virus-like particle (VLP).

5. The use of any one of claims 1 to 4, wherein the at least one purified viral L1 protein and the second active pharmaceutical ingredient and pharmaceutically acceptable carrier are in a unitary dosage form.